fda warning letter semaglutide october 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ FDA targets supplement reviews and

On 7 April, the FDA published several warning letters, including a batch to companies that the agency said are marketing GLP-1 products, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) products, and triple agonist (GLP-1/GIP/glucagon) products without regulatory approval

What to do if you drew the wrong dose Mistakes happen

Broth-based soups provide hydration alongside nutrition and are often well-tolerated even when solid foods feel challenging

Timing matters: sip before and after activity, add a pinch of salt to meals if blood pressure allows, and limit alcohol

Long-term considerations start becoming relevant here